Davies Sarah I, Barrett John, Wong Susan, Chang Mark Jesse, Muranski Pawel J, Brownell Isaac
Hematology Branch, National Heart, Lung, and Blood Institute, Bethesda, MD, United States.
Department of Microbiology & Immunology, Georgetown University Medical Center, Washington, DC, United States.
Front Immunol. 2020 Dec 9;11:592721. doi: 10.3389/fimmu.2020.592721. eCollection 2020.
Virus positive Merkel cell carcinoma (VP-MCC) is an aggressive but immunogenic skin malignancy driven by Merkel cell polyomavirus (MCPyV) T antigen (TAg). Since adoptive T cell transfer (ACT) can be effective against virus-driven malignancies, we set out to develop a methodology for generating MCPyV TAg specific T cells. MCPyV is a common, asymptomatic infection and virus-exposed healthy donors represent a potential source of MCPyV TAg specific T cells for ACT. Virus specific T cells were generated using monocyte-derived dendritic cells (moDCs) pulsed with MCPyV TAg peptide libraries and co-cultured with autologous T cells in supplemented with pro-inflammatory and homeostatic cytokines for 14 days. Specific reactivity was observed predominantly within the CD4 T cell compartment in the cultures generated from 21/46 random healthy donors. Notably, responses were more often seen in donors aged 50 years and older. TAg specific CD4 T cells specifically secreted Th1 cytokines and upregulated CD137 upon challenge with MCPyV TAg peptide libraries and autologous transduced antigen presenting cells. Expanded T cells from healthy donors recognized epitopes of both TAg splice variants found in VP-MCC tumors, and minimally expressed exhaustion markers. Our data show that MCPyV specific T cells can be expanded from healthy donors using methods appropriate for the manufacture of clinical grade ACT products.
病毒阳性默克尔细胞癌(VP-MCC)是一种侵袭性但具有免疫原性的皮肤恶性肿瘤,由默克尔细胞多瘤病毒(MCPyV)T抗原(TAg)驱动。由于过继性T细胞转移(ACT)可有效对抗病毒驱动的恶性肿瘤,我们着手开发一种生成MCPyV TAg特异性T细胞的方法。MCPyV是一种常见的无症状感染,接触过病毒的健康供体是用于ACT的MCPyV TAg特异性T细胞的潜在来源。使用用MCPyV TAg肽库脉冲处理的单核细胞衍生树突状细胞(moDC)生成病毒特异性T细胞,并在补充促炎和稳态细胞因子的情况下与自体T细胞共培养14天。在来自21/46名随机健康供体的培养物中,主要在CD4 T细胞区室中观察到特异性反应。值得注意的是,50岁及以上的供体中更常出现反应。在用MCPyV TAg肽库和自体转导的抗原呈递细胞刺激后,TAg特异性CD4 T细胞特异性分泌Th1细胞因子并上调CD137。来自健康供体的扩增T细胞识别在VP-MCC肿瘤中发现两种TAg剪接变体的表位,并且极少表达耗竭标志物。我们的数据表明,使用适合生产临床级ACT产品的方法,可以从健康供体中扩增出MCPyV特异性T细胞。